Volume 12, Issue 2

Neurotherapeutics is now archived and no longer receiving submissions with this publisher. All articles published in the journal during its time with Springer will remain fully searchable through our websites.

Search all Neurotherapeutics articles

April 2015

The Spectrum of Motor Neuron Diseases: From Childhood SMA to Adult ALS

22 articles in this issue

The Spectrum of Motor Neuron Diseases: From Childhood Spinal Muscular Atrophy to Adult Amyotrophic Lateral Sclerosis
Stacey A. Sakowski
Eva L. Feldman
Editorial 21 March 2015 Pages: 287 - 289
The Genetics of Spinal Muscular Atrophy: Progress and Challenges
Michelle A. Farrar
Matthew C. Kiernan
Review 21 November 2014 Pages: 290 - 302
Spinal Muscular Atrophy Therapeutics: Where do we Stand?
Constantin d’Ydewalle
Charlotte J. Sumner
Review Open access 29 January 2015 Pages: 303 - 316
Challenges in the Understanding and Treatment of Amyotrophic Lateral Sclerosis/Motor Neuron Disease
Jeffrey Rosenfeld
Michael J. Strong
Review 09 January 2015 Pages: 317 - 325
The Spectrum of C9orf72-mediated Neurodegeneration and Amyotrophic Lateral Sclerosis
Johnathan Cooper-Knock
Janine Kirby
Pamela J. Shaw
Review Open access 03 March 2015 Pages: 326 - 339
Linking RNA Dysfunction and Neurodegeneration in Amyotrophic Lateral Sclerosis
Sami J. Barmada
Review 18 February 2015 Pages: 340 - 351
TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets
Emma L. Scotter
Han-Jou Chen
Christopher E. Shaw
Review Open access 05 February 2015 Pages: 352 - 363
Protective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis
Kristopher G. Hooten
David R. Beers
Stanley H. Appel
Review 08 January 2015 Pages: 364 - 375
Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?
Katharine A. Nicholson
Merit E. Cudkowicz
James D. Berry
Review 21 February 2015 Pages: 376 - 383
Clinical Measures of Disease Progression in Amyotrophic Lateral Sclerosis
Seward B. Rutkove
Review 13 January 2015 Pages: 384 - 393
Patient-Perceived Outcomes and Quality of Life in ALS
Zachary Simmons
Review 11 December 2014 Pages: 394 - 402
Neuroimaging as a New Diagnostic Modality in Amyotrophic Lateral Sclerosis
Esther Verstraete
Bradley R. Foerster
Review 20 March 2015 Pages: 403 - 416
Being PRO-ACTive: What can a Clinical Trial Database Reveal About ALS?
Neta Zach
David L. Ennist
Melanie L. Leitner
Review 23 January 2015 Pages: 417 - 423
RNA-targeted Therapeutics for ALS
Linga V. Reddy
Timothy M. Miller
Review 10 March 2015 Pages: 424 - 427
Recent Advances and the Future of Stem Cell Therapies in Amyotrophic Lateral Sclerosis
Stephen A. Goutman
Kevin S. Chen
Eva L. Feldman
Review 17 March 2015 Pages: 428 - 448
Gaps Between Aims and Achievements in Therapeutic Modification of Neuronal Damage (“Neuroprotection”)
Heinz Wiendl
Christian Elger
Stefan Schwab
Original Article Open access 14 March 2015 Pages: 449 - 454
A Double-Blinded, Randomized, Placebo-Controlled Trial to Evaluate Efficacy, Safety, and Tolerability of Single Doses of Tirasemtiv in Patients with Acetylcholine Receptor-Binding Antibody-Positive Myasthenia Gravis
Donald B. Sanders
Jeffrey Rosenfeld
for the Tirasemtiv in Myasthenia Gravis Study Group
Original Article Open access 06 March 2015 Pages: 455 - 460
Regulation of Intracellular Copper by Induction of Endogenous Metallothioneins Improves the Disease Course in a Mouse Model of Amyotrophic Lateral Sclerosis
Eiichi Tokuda
Shunsuke Watanabe
Shin-ichi Ono
Original Article 12 March 2015 Pages: 461 - 476
Rescue of Methyl-CpG Binding Protein 2 Dysfunction-induced Defects in Newborn Neurons by Pentobarbital
Dongliang Ma
Su-In Yoon
Eyleen L. K. Goh
Original Article Open access 10 March 2015 Pages: 477 - 490
Diffusion Efficiency and Bioavailability of Resveratrol Administered to Rat Brain by Different Routes: Therapeutic Implications
Xiao-Hong Shu
Li-Li Wang
Jia Liu
Original Article 15 January 2015 Pages: 491 - 501
Enhanced Retinal Ganglion Cell Survival in Glaucoma by Hypoxic Postconditioning After Disease Onset
Jeffrey M. Gidday
Lihong Zhang
Yanli Zhu
Original Article 31 December 2014 Pages: 502 - 514
Erratum to: TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets
Emma L. Scotter
Han-Jou Chen
Christopher E. Shaw
Erratum 12 March 2015 Pages: 515 - 518

Volume 12, Issue 2

The Spectrum of Motor Neuron Diseases: From Childhood Spinal Muscular Atrophy to Adult Amyotrophic Lateral Sclerosis

The Genetics of Spinal Muscular Atrophy: Progress and Challenges

Spinal Muscular Atrophy Therapeutics: Where do we Stand?

Challenges in the Understanding and Treatment of Amyotrophic Lateral Sclerosis/Motor Neuron Disease

The Spectrum of C9orf72-mediated Neurodegeneration and Amyotrophic Lateral Sclerosis

Linking RNA Dysfunction and Neurodegeneration in Amyotrophic Lateral Sclerosis

TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets

Protective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis

Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?

Clinical Measures of Disease Progression in Amyotrophic Lateral Sclerosis

Patient-Perceived Outcomes and Quality of Life in ALS

Neuroimaging as a New Diagnostic Modality in Amyotrophic Lateral Sclerosis

Being PRO-ACTive: What can a Clinical Trial Database Reveal About ALS?

RNA-targeted Therapeutics for ALS

Recent Advances and the Future of Stem Cell Therapies in Amyotrophic Lateral Sclerosis

Gaps Between Aims and Achievements in Therapeutic Modification of Neuronal Damage (“Neuroprotection”)

A Double-Blinded, Randomized, Placebo-Controlled Trial to Evaluate Efficacy, Safety, and Tolerability of Single Doses of Tirasemtiv in Patients with Acetylcholine Receptor-Binding Antibody-Positive Myasthenia Gravis

Regulation of Intracellular Copper by Induction of Endogenous Metallothioneins Improves the Disease Course in a Mouse Model of Amyotrophic Lateral Sclerosis

Rescue of Methyl-CpG Binding Protein 2 Dysfunction-induced Defects in Newborn Neurons by Pentobarbital

Diffusion Efficiency and Bioavailability of Resveratrol Administered to Rat Brain by Different Routes: Therapeutic Implications

Enhanced Retinal Ganglion Cell Survival in Glaucoma by Hypoxic Postconditioning After Disease Onset

Erratum to: TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets

Navigation